Skip to main content
. 2021 May 24;3(4):565–575.e1. doi: 10.1016/j.xkme.2021.03.009

Table 3.

Characteristics of Receiving Versus Not Receiving Kidney Failure Treatment Modality Education

Characteristic All Enrolled Patients (N = 117) Kidney Failure Treatment Modality Education
Received (n = 33) Not Received (n = 84) Pa
Age, y 71 [60-80] 71 [59-79] 70 [61-80] 0.73
Female sex 50 (43%) 10 (30%) 40 (48%) 0.08
eGFR, mL/min/1.73 m2 21.4 [16.6-25.7] 22.3 [16.6-25.7] 20.9 [16.6-25.5] 0.81
KFRE score 0.16 [0.10-0.28] 0.17 [0.08-0.29] 0.16 [0.10-0.28] 0.95
Charlson Comorbidity Index score 6 [4-7] 5 [3-6] 6 [4-8] 0.01
Diabetes 83 (71%) 22 (67%) 61 (73%) 0.52
Cardiovascular disease 65 (56%) 65 (56%) 79 (63%) 0.26
Time on registry as of June 30, 2018 8 [8-9] 9 [9-10] 8 [8,9] 0.05
 1-3 mo 2 (1.7%) 0 (0.0%) 2 (2.4%)
 4-6 mo 12 (10.3%) 4 (12.1%) 8 (9.5%) 0.29
 7-9 mo 79 (67.5%) 19 (57.6%) 60 (71.4%)
 10-12 mo 24 (20.5%) 10 (30.3%) 14 (16.7%)
Time enrolled as of June 30, 2018 6 [4-9] 8 [5-9] 6 [3-8] 0.02
 1-3 mo 25 (21.4%) 3 (9.1%) 22 (26.2%)
 4-6 mo 34 (29.1%) 11 (33.3%) 23 (27.4%) 0.03
 7-9 mo 43 (36.8%) 11 (33.3%) 32 (38.1%)
 10-12 mo 15 (12.8%) 8 (24.2%) 7 (8.3%)
Years in nephrology 3 [1-6] 3 [1-6] 4 [1-7] 0.69

Note: Values expressed as median [interquartile range] or number (percent).

Abbreviations: eGFR, estimated glomerular filtration rate; KFRE, Kidney Failure Risk Equation.

a

Chi-square tests for categorical measures and Kruskal-Wallis tests for continuous measures.